Abstract:Drug resistance significantly impairs the efficacy of AIDS therapy. Therefore, precise prediction of resistant viral mutants is particularly useful for developing effective drugs and designing therapeutic regimen. In this study, we applied a structure‐based computational approach to predict mutants of the HIV‐1 protease resistant to the seven FDA approved drugs. We analyzed the energetic pattern of the protease‐drug interaction by calculating the molecular interaction energy components (MIECs) between the drug and the protease residues. Support vector machines (SVMs) were trained on MIECs to classify protease mutants into resistant and nonresistant categories. The high prediction accuracies for the test sets of cross‐validations suggested that the MIECs successfully characterized the interaction interface between drugs and the HIV‐1 protease. We conducted a proof‐of‐concept study on a newly approved drug, darunavir (TMC114), on which no drug resistance data were available in the public domain. Compared with amprenavir, our analysis suggested that darunavir might be more potent to combat drug resistance. To quantitatively estimate binding affinities of drugs and study the contributions of protease residues to causing resistance, linear regression models were trained on MIECs using partial least squares (PLS). The MIEC‐PLS models also achieved satisfactory prediction accuracy. Analysis of the fitting coefficients of MIECs in the regression model revealed the important resistance mutations and shed light into understanding the mechanisms of these mutations to cause resistance. Our study demonstrated the advantages of characterizing the protease‐drug interaction using MIECs. We believe that MIEC‐SVM and MIEC‐PLS can help design new agents or combination of therapeutic regimens to counter HIV‐1 protease resistant strains. Proteins 2009. © 2008 Wiley‐Liss, Inc.

Random Forest Algorithm for Prediction of HIV Drug Resistance

Prediction of HIV Drug Resistance by Combining Sequence and Structural Properties

Quantitative Prediction of Human Immunodeficiency Virus Drug Resistance

Computer Prediction of Drug Resistance Mutations in Proteins

A Robust Random Forest Prediction Model for Mother-to-Child HIV Transmission Based on Individual Medical History

Multi-Drug Artificial Neural Network Models for Predicting HIV-1 RTI Resistance

Harnessing Artificial Intelligence for HIV Drug Resistance Prediction and Personalized Treatment

Random forest machine learning algorithm predicts virologic outcomes among HIV infected adults in Lausanne, Switzerland using electronically monitored combined antiretroviral treatment adherence

Random Forest for Genomic Prediction

Predicting Treatment Outcomes in Patients with Drug-Resistant Tuberculosis and Human Immunodeficiency Virus Coinfection, Using Supervised Machine Learning Algorithm

Random Forest Algorithm for Enhanced Prediction of Drug Target Interactions

HIV-1 CRF01_AE coreceptor usage prediction using kernel methods based logistic model trees

Random Forest for Bioinformatics

ggRandomForests: Exploring Random Forest Survival

Selecting anti-HIV therapies based on a variety of genomic and clinical factors

Evaluating the Impact of Missing Data Imputation through the use of the Random Forest Algorithm

Comparison of Algorithms That Interpret Genotypic Hiv-1 Drug Resistance to Determine the Prevalence of Transmitted Drug Resistance

Prediction of Heart Diseases using Random Forest

Detecting and Understanding Combinatorial Mutation Patterns Responsible for HIV Drug Resistance

Predicting Drug Resistance of the HIV‐1 Protease Using Molecular Interaction Energy Components

Heart failure prediction based on random forest algorithm using genetic algorithm for feature selectio